Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of standard intensive chemotherapy versus CPX-351-containing intensive chemotherapy in newly diagnosed intermediate/adverse-risk AML
2023-503670-21-00Phase 3Authorised
- Sponsor
- University Hospital Ulm
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cytarabine and daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by University Hospital Ulm. Primary endpoint: Event-free survival. Planned start Aug 2019; status: authorised.
02
Drugs
cytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-503670-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503670-21-00.